Healthy subjects.
Conditions
Interventions
Intervention 1: Oral administration of placebo. Intervention 2: Oral administration of 200 mg soft capsule of Eucalyptus.
Placebo
Treatment - Drugs
Oral administration of 200 mg soft capsule of Eucalyptus
Sponsors
Research and Technology Deputy, Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
19 Years to 24 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: female; ages between 19-24 years old. Exclusion criteria: chronic disease (i.e. diabetes mellitus, hypertension, epilepsy and etc); smoking; under regular medication
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean of RR interval. Timepoint: before and after administration of placebo or drug. Method of measurement: Time domain analysis of ECG.;Standard deviation of RR interval. Timepoint: before and after administration of placebo or drug. Method of measurement: Time domain analysis of ECG. | — |
Secondary
| Measure | Time frame |
|---|---|
| High frequency power spectrum (a quantity index of cardiac vagal function). Timepoint: before and after administration of placebo or drug. Method of measurement: Frequency domain analysis of ECG.;Low frequency power spectrum. Timepoint: before and after administration of placebo or drug. Method of measurement: Frequency domain analysis of ECG. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactEsmaeil Akbari
Department of Physiology, School of Medicine, Mazandaran University of Medical Sciences, Sari
Outcome results
None listed